Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | RET |
| Variant | D898V |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | RET D898V lies within the protein kinase domain of the Ret protein (UniProt.org). D898V has been identified in the scientific literature (PMID: 23526464), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
RET mutant RET D898V |
| Transcript | NM_020975.6 |
| gDNA | chr10:g.43120166A>T |
| cDNA | c.2693A>T |
| Protein | p.D898V |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_020630.5 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_001406760.1 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_020630 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_020975 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_001406743.1 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_001406744.1 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_020630.7 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_001406769.1 | chr10:g.43126624A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_020975.5 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_020975.6 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_001406759.1 | chr10:g.43120166A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| NM_001406772.1 | chr10:g.43126624A>T | c.2693A>T | p.D898V | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET D898V | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET D898V in culture (PMID: 23526464). | 23526464 |